Kidney Cancer Coalition & KCAN: Stronger Together

Kidney Cancer Coalition and KCAN have joined forces to accelerate life-saving research and clinical trials for kidney cancer.

The union of these two complementary charitable organizations represents a promising step for the kidney cancer community.

Together, we’ll be known as KidneyCAN—carrying that name forward while embracing the “CAN” legacy to reinforce our driven and optimistic vision for our role in the fight against this deadly disease.

Battling what is among the most prevalent forms of cancer among men (#6) and women (#10) in the U.S.*—yet still among the most under-funded and under-recognized cancers— patients, caregivers, advocates, and scientists are in dire need of greater awareness, funding, and action. That is our focus.

As one, we bring proven effectiveness at raising money for research—from grassroots efforts, to private contributions and corporate grants, up through substantial federal funding. Our impact in just four combined years of existence includes:

Spearheading efforts to initiate a $45 million Congressional grant program for research;

Raising over $1 million through local efforts and events including our “Rock the Cure” fundraisers, with over $625,000 already put to work in research labs and studies;

Leading the first-ever grassroots-funded clinical trial for kidney cancer; and

Earning a reputation for being extremely efficient at deploying capital directly to clinical and scientific endeavors in pursuit of breakthroughs.

Our founders—Brenda and Ralph Knapp, who started KC Coalition in 2016, and Bryan Lewis, who formed KCAN in 2017—recognized the potential benefits of pooling their strengths and resources. These three devoted leaders have personal experiences with kidney cancer, as patients, caregivers, and advocates. Their commitment to the cause is profound.

Brenda, Ralph, and Bryan remain confident that we “CAN” find a cure in our lifetime, despite the historical lack of funding—particularly compared to other forms of cancer—which continues to leave a severe shortage of trials resulting in roughly 15,000 deaths in the U.S. each year.*

COMING SOON

KIDNEY CANCER RESEARCH SUMMIT

#KCRS2019

SEPTEMBER 2019

PHILADELPHIA, PA

Bryan Lewis, President & Co-Founder

Co-Chairs Drs. Hans Hammers & Tony Choueiri

Brenda Knapp, Treasurer & Co-Founder

We are proud to host the 1st annual Kidney Cancer Research Summit bringing together renowned scientists, young investigators, industry and research advocates.

We had a successful advocacy day on the Hill March 12th

Thank you to all who let your voice be heard

In the News

June 4, 2019

World Kidney Cancer Day June 20, 2019

20th June 2019 is World Kidney Cancer Day. “We need to talk” to make our community aware of this terrible...
Read More
May 7, 2019

Keytruda-Inlyta Combo Approved by FDA for Untreated Advanced Kidney Cancer immuno-oncologynews.com

immuno-oncologynews.com/2019/04/30/keytruda-inlyta-combo-approved-fda-untreated-advanced-kidney-cancer/Ines Martins, PhDApril 30, 2019 The U.S. Food and Drug Administration (FDA) has approved a combination of Keytruda (pembrolizumab) plusInlyta (axitinib) for the initial treatment...
Read More
April 16, 2019 / News Page

Budget Caps & Cancer Research. Is there a connection?

By our Constitution, our elected representatives annually decide how much money our government will spend on government programs. This year...
Read More
April 16, 2019

U.S. Senate Support for Kidney Cancer

This week U.S. Senator Kirsten Gillibrand (D-NY) joined with several other colleagues requesting support for an increase in kidney cancer...
Read More
March 30, 2019 / News Page

Harnessing T-cell “stemness” Could Enhance Cancer Immunotherapy

NIH researchers are exploring ways to help T-cells used for immunotherapy not only last longer but replicate and grow. Read...
Read More
1 2 3 5
Donate Now!

Since our inception in 2016, we have proudly given over $625,000 to Kidney Cancer Research!

WE ARE A GRASSROOTS ORGANIZATION DEDICATED TO MAKING A DIFFERENCE IN THE KIDNEY CANCER COMMUNITY

Funded major projects to date include:

  • RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.

  • Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.

 Our primary sources of support are donations from the general public and fundraising.  

Our mission is to abolish Kidney Cancer as a threat to the life and health of patients through advocacy and accelerating research by  offering direct financial support for clinical and laboratory researchers with promising ideas.

LEARN MORE

Kidney Cancer strikes 63,340/year

14,970/year die from the disease

We want to help change those statistics!